Granahan Investment Management LLC Boosts Holdings in Stevanato Group S.p.A. (NYSE:STVN)

Granahan Investment Management LLC boosted its holdings in Stevanato Group S.p.A. (NYSE:STVN) by 95.2% in the 4th quarter, HoldingsChannel reports. The firm owned 226,401 shares of the company’s stock after purchasing an additional 110,418 shares during the quarter. Granahan Investment Management LLC’s holdings in Stevanato Group were worth $4,933,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Van Berkom & Associates Inc. bought a new stake in Stevanato Group in the fourth quarter worth $39,000. Johnson Financial Group Inc. purchased a new stake in shares of Stevanato Group during the 4th quarter valued at about $41,000. Wells Fargo & Company MN lifted its holdings in shares of Stevanato Group by 680.3% in the 4th quarter. Wells Fargo & Company MN now owns 3,246 shares of the company’s stock valued at $71,000 after acquiring an additional 2,830 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Stevanato Group by 1,457.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company’s stock worth $123,000 after acquiring an additional 5,291 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Stevanato Group by 202.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,413 shares of the company’s stock worth $162,000 after acquiring an additional 4,965 shares during the last quarter.

Stevanato Group Stock Performance

Shares of Stevanato Group stock opened at €23.92 ($26.88) on Friday. The company has a market capitalization of $7.24 billion, a PE ratio of 50.89, a price-to-earnings-growth ratio of 7.18 and a beta of 0.51. Stevanato Group S.p.A. has a 52 week low of €16.56 ($18.61) and a 52 week high of €24.90 ($27.98). The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. The stock’s fifty day moving average is €21.12 and its two-hundred day moving average is €20.98.

Stevanato Group (NYSE:STVN) last released its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of €0.20 ($0.22). The company had revenue of €352.68 million during the quarter, compared to analysts’ expectations of €346.26 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. As a group, analysts expect that Stevanato Group S.p.A. will post 0.5 earnings per share for the current year.

Stevanato Group Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, July 17th. Investors of record on Thursday, June 5th will be paid a $0.0613 dividend. The ex-dividend date of this dividend is Thursday, June 5th. This represents a yield of 0.3%. This is a boost from Stevanato Group’s previous annual dividend of $0.05. Stevanato Group’s dividend payout ratio is 11.76%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Stephens upgraded Stevanato Group to a “strong-buy” rating in a report on Monday, April 21st. William Blair reiterated an “outperform” rating on shares of Stevanato Group in a research report on Friday, March 7th. Finally, UBS Group lowered their target price on shares of Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of €25.70 ($28.88).

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.